Orient Pharma CoROCO:4166 +5.02%56 Gross Margin % is 60.10% as of Dec. 2025, which is 147% above its 10-year median of 24.30. GuruFocus rates ROCO:4166 with a GF Score™ of 56/100 and a GF Value™ of NT$45.09 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 938 Drug Manufacturers companies, Orient Pharma Co ranks better than 63.33% on this metric.
The historical rank and industry rank for Orient Pharma Co's Gross Margin % or its related term are showing as below:
ROCO:4166'
s Gross Margin % Range Over the Past 10 Years
Min: -15.72 Med: 24.3 Max: 56.47
Current: 56.47
During the past 13 years, the highestGross Margin % of Orient Pharma Co was 56.47%. The lowest was -15.72%. And the median was 24.30%.
ROCO:4166's Gross Margin % is ranked better than 63.33% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs ROCO:4166: 56.47
Orient Pharma Co had a gross margin of 60.10% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Orient Pharma Co was 25.10% per year.
Orient Pharma Co (ROCO:4166) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Orient Pharma Co had a gross margin of 60.10% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Orient Pharma Co Gross Margin % Related Terms
Orient Pharma Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for Orient Pharma Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orient Pharma Co Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Orient Pharma Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Orient Pharma Co (ROCO:4166) has a Gross Margin % of 60.10% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Orient Pharma Co and its competitors. This is 147% above median its historical median of 24.30. According to the industry distribution chart, Orient Pharma Co ranks #344 out of 938 companies in the Drug Manufacturers industry, placing it in the top 36.7%.
Is Orient Pharma Co's Gross Margin % too high?
Orient Pharma Co's current Gross Margin % of 60.10% is 147% above median its 10-year median of 24.30. The Drug Manufacturers industry median Gross Margin % is 48.54. Orient Pharma Co's value of 60.10% is 23.8% above this industry median. Based on the distribution chart, Orient Pharma Co ranks #344 out of 938 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Orient Pharma Co has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orient Pharma Co ranks #344 out of 938 companies for Gross Margin %. This puts Orient Pharma Co in the upper half of its industry. The industry median Gross Margin % is 48.54. Orient Pharma Co's value of 60.10% is 23.8% above this benchmark. While the company's 10-year median is 24.30 vs. the industry median of 48.54, Orient Pharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orient Pharma Co's current Gross Margin % of 60.10% is 23.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Orient Pharma Co and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Pharma Co's current Gross Margin % is 60.10%, which is 147% above median its own 10-year median of 24.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$45.09, compared to a current price of NT$27.20 — trading 39.7% below its estimated fair value. The current Gross Margin % is 60.10%, which is 147% above median its 10-year median of 24.30 and 23.8% above the Drug Manufacturers industry median of 48.54. Orient Pharma Co's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current Gross Margin % is 60.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?
Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued.
The current stock price of NT$27.20 is trading 39.7% below its estimated GF Value™ of NT$45.09.
GuruFocus considers Orient Pharma Co to be Significantly Undervalued.
Key valuation signals for ROCO:4166:
Gross Margin %: 60.10% (147% above median its 10-year median of 24.30)
GF Value™: NT$45.09 vs. price of NT$27.20 (39.7% below fair value)
Industry Position: 23.8% above the Drug Manufacturers median (#344 of 938)
No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
56GF Score
Get the complete analysis for ROCO:4166
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4166 has been successfully added to your 
